Share your opinion and earn yourself a free Motley Fool premium report!

We are looking for Fools to join a 75 minute online independent market research forum on 15th / 16th December.

To find out more and express your interest please click here

What This Top Dividend Portfolio Is Holding Now: GlaxoSmithKline plc, Royal Dutch Shell Plc And Antofagasta plc

GlaxoSmithKline plc (LON:GSK), Royal Dutch Shell Plc (LON:RDSB) and Antofagasta (LON:ANTO) are favoured holdings of Merchants Trust plc (LON:MRCH).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Merchants Trust (LSE: MRCH) has delivered 33 consecutive years of dividend increases, and carries a trailing yield of 4.8%. Picking great dividend shares has helped Merchants outperform the FTSE All-Share Index over the past three, five and 10 years.

Heavyweight high yielder GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US), biggest holding and top yielder Royal Dutch Shell (LSE: RDSB) and new buy Antofagasta (LSE: ANTO) catch my eye in Merchants’ portfolio.

GlaxoSmithKline

Top FTSE 100 pharmaceuticals firm GlaxoSmithKline still does blockbuster drugs, but Merchants likes the way the company has been consolidating its global leadership positions in vaccines and consumer health, where there are “scale advantages” and “limited risk from generic competition”.

Earlier this month, Glaxo’s management set out its expectations for the reconfigured group. The Board anticipates an earnings decline in the current year at a percentage rate in the high teens, but expects to deliver a compound annual growth rate of mid-to-high single digits over the five-year period 2016-2020.

Management intends to peg the dividend at 80p a share this year and for the next two years. The payout equates to an annual yield of 5.5% for buyers of the shares at the current price of 1,442p. There’ll also be an additional 20p special dividend this year. From 2018, the prospects for dividend increases look good, if management delivers the mid-to-high single digits earnings growth it expects.

Royal Dutch Shell

Like Glaxo, oil supermajor Shell has put a near-term dividend increase on hold. The company has said it intends to pay an unchanged $1.88 a share this year — which may extend to next year, with management guiding on “at least that amount in 2016”.

At current exchange rates, the dollar dividend translates into a sterling payout of 121.3p, giving a yield of 6.1% for buyers of the shares at the current price of 2,000p.

The reason for the temporary halt to a dividend increase is Shell’s agreed £47bn acquisition of BG Group, announced last month. This deal is set to cement Shell’s leading position in the global LNG market and give the company a significant stake in attractive Brazilian assets. That should be good for shareholders’ dividends in the long run, and Merchants Trust is “supportive of the rationale for this deal”.

Antofagasta

Merchants has taken a new position in low-cost copper producer Antofagasta, explaining:

“Copper is an attractive commodity as supply is limited and increasingly expensive to develop whilst demand is broadly spread. Over time supply constraints should lead to a price recovery from depressed levels. The company has one of strongest balance sheets in the sector and is reasonably priced”.

Antofagasta’s dividend yield is a lowly 1.75% in the current subdued environment, but the company has a history of regularly returning excess capital to shareholders via special dividends when business is booming. At the current depressed share price of 775p, the kind of payouts we’ve seen on occasions in the past — and may see again in the future when the copper price recovers — would equate to a yield of 8%-9% during those years.

G A Chester has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young woman holding up three fingers
Investing Articles

Want to start investing in 2026? 3 things to get ready now!

Before someone is ready to start investing in the stock market, our writer reckons it could well be worth them…

Read more »

Investing Articles

Can the stock market continue its strong performance into 2026?

Will the stock market power ahead next year -- or could its recent strong run come crashing down? Christopher Ruane…

Read more »

Businessman hand stacking money coins with virtual percentage icons
Investing Articles

Here’s how someone could invest £20k in an ISA to target a 7% dividend yield in 2026

Is 7% a realistic target dividend yield for a Stocks and Shares ISA? Christopher Ruane reckons that it could be.…

Read more »

A quiet morning and an empty Victoria Street in Edinburgh's historic Old Town.
Investing Articles

How little is £1k invested in Greggs shares in January worth now?

Just how much value have Greggs shares lost this year -- and why has our writer been putting his money…

Read more »

Businessman using pen drawing line for increasing arrow from 2024 to 2025
Investing Articles

This cheap FTSE 100 stock outperformed Barclays, IAG, and Games Workshop shares in 2025 but no one’s talking about it

This FTSE stock has delivered fantastic gains in 2025, outperforming a lot of more popular shares. Yet going into 2026,…

Read more »

Close-up of British bank notes
Investing Articles

100 Lloyds shares cost £55 in January. Here’s what they’re worth now!

How well have Lloyds shares done in 2025? Very well is the answer, as our writer explains. But they still…

Read more »

Thoughtful man using his phone while riding on a train and looking through the window
Investing Articles

How much do you need in an ISA to target £2,000 a month of passive income

Our writer explores a passive income strategy that involves the most boring FTSE 100 share. But when it comes to…

Read more »

Investing Articles

£5,000 invested in a FTSE 250 index tracker at the start of 2025 is now worth…

Despite underperforming the FTSE 100, the FTSE 250 has been the place to find some of the UK’s top growth…

Read more »